



## **Ziccum AB (publ) Flagging message (regulatory)**

(Stockholm May 29, 2019) **Ziccum AB (publ) received information on the change in the number of shares related to Inhalation Science AB's sale of 400,000 shares on May 23, 2019.**

Inhalation Science AB had 2 190 000 shares in Ziccum before the sale, corresponding to 36.5% of the capital and votes. After the transaction on May 23, the holding is 29.8%. The flagging message is published when the holding passes below 30% after the change in the number of shares in Ziccum.

*PLEASE NOTE: This is an unofficial translation of the original notice, which is in Swedish. In case of discrepancies, the Swedish version shall prevail.*

**For more information about Ziccum, please contact:**

Göran Conradson: CEO Ziccum AB

E-mail: [conradson@ziccum.com](mailto:conradson@ziccum.com)

Mob: +46 709 61 55 99

### **About Ziccum**

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company's patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets—and open up new ones.

*The information above was provided by Ziccum AB (publ) through the above contact person, for publication on May 29, 2019.*